CD276
CD276 antigen
As of the edition of 20 October 2026, CD276 (CD276 antigen, UniProt Q5ZPR3) has 12 drugs tested at it and 10 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q5ZPR3
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 3
- Disease areas
- Cancer; Urinary and reproductive; Lungs and airways; Pregnancy and women's health; Skin and connective tissue; Hormones; Digestive system; Nervous system
- Registered trials of its drugs
- 36
Drugs at this target
| Status | Count |
|---|---|
| Active | 5 |
| Stopped | 6 |
| Status not established | 1 |
| Total | 12 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Enoblituzumab | Stopped | Phase 3 | none listed |
| Omburtamab | Stopped | Phase 3 | none listed |
| SYS6043 | Active | Phase 3 | none listed |
| Vobramitamab duocarmazine | Stopped | Phase 2 | none listed |
| GSK5764227 | Active | Phase 2 | none listed |
| IBB0979 | Active | Phase 2 | none listed |
| 8H9 131I | Stopped | No phase stated | none listed |
| DS-5573a | Stopped | Phase 1 | none listed |
| IBI3001 | Active | Phase 1 | none listed |
| IBI334 | Status not established | Phase 2 | none listed |
| NEOK001 | Active | Phase 1 | none listed |
| TAK-280 | Stopped | Phase 2 | none listed |
12 of 12 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Engaged | 6 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| MacroGenics | Route A |
| Y-mAbs Therapeutics | Route A |
| Daiichi Sankyo | Route A |
The other 7 companies at CD276
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at CD276, ranked, with the facts behind eachRequest access. Nothing is shown until you do.